• 1
    Silverberg SG, Chitale AR. Assessment of significance of proportions of intraductal and infiltrating tumor growth in ductal carcinoma of the breast. Cancer 1973; 32: 8307.
  • 2
    Matsukuma A, Enjoji M, Toyoshima S. Ductal carcinoma of the breast: an analysis of proportions of intraductal and invasive components. Pathol Res Pract 1991; 187: 627.
  • 3
    World Health Organization (WHO). Histological typing of breast tumours, ed. 2. International histological classification of tumors, no. 2, Geneva: WHO, 1981.
  • 4
    Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ: frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989; 63: 61824.
  • 5
    Patchefsky AS, Schwartz GF, Finkelstein SD, Prestipino A, Sohn SE, Singer JS, et al. Heterogeneity of intraductal carcinoma of the breast. Cancer 1989; 63: 73141.
  • 6
    Moriya T, Silverberg SG. Intraductal carcinoma of the breast: characterization and significance of different histologic patterns [abstract]. Mod Pathol 1991; 4: 13A.
  • 7
    Meyer JS. Cell kinetics of histologic variants of in situ breast carcinoma. Breast Cancer Res Treat 1986; 7: 17180.
  • 8
    Lodato RF, Maguire HC, Green MI, Weiner DB, LiVolsi VA. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 1990; 3: 44954.
  • 9
    Fentiman IS, Fagg N, Millis RR, Hayward JL. In situ ductal carcinoma of the breast: implications of disease pattern and treatment. Eur J Surg Oncol 1986; 12: 2616.
  • 10
    Hardman PDJ, Worth A, Lee U. The risk of occult invasive breast cancer after excisional biopsy showing in-situ ductal carcinoma of comedo pattern. Can J Surg 1989; 32: 5660.
  • 11
    Ketcham AS, Moffat FL. Vexed surgeons, perplexed patients, and breast cancers which may not be cancer. Cancer 1990; 65: 38793.
  • 12
    Silverstein MJ, Waisman JR, Gamagami P, Gierson ED, Colburn WJ, Rosser RJ, et al. Intraductal carcinoma of the breast (208 cases): clinical factors influencing treatment choice. Cancer 1990; 66: 1028.
  • 13
    Allred DC, Clark GM, Molina R, Tandon AF, Schnitt SJ, Gilchrist KW, et al. Overexpression of Her-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992; 23: 9749.
  • 14
    Fisher ER, Sass R, Fisher B, Wickerham L, Paik SM, and collaborating NSABP investigators. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 6): I. intraductal carcinoma (DCIS). Cancer 1986; 57: 197208.
  • 15
    Schuh ME, Nemoto T, Penetrante RB, Rosner D, Dao TL. Intraductal carcinoma: analysis of presentation, pathologic findings, and outcome of disease. Arch Surg 1986; 121: 13037.
  • 16
    Ichihara S, Aoyama H, Matsuyama T, Kubo K, Tamura J. Relationship between the extent of intraductal component and that of the invasive component in ductal carcinoma of the breast. Acta Pathol Jpn 1989; 39: 78694.
  • 17
    Lash RH, Bauer TW, Medendorp SV. Prognostic significance of the proportion of intraductal and infiltrating ductal carcinoma in women treated by partial mastectomy. Surg Pathol 1990; 3: 4757.
  • 18
    Verhoeven D, Van Marck E. Proliferation, basement membrane changes, metastasis and vascularization patterns in human breast cancer. Pathol Res Pract 1993; 189: 85161.
  • 19
    Ridolfi RL, Rosen PP, Port A, Kinne D, Miké V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977; 40: 136585.
  • 20
    Wargotz ES, Silverberg SG. Medullary carcinoma of the breast: a clinicopathologic study with appraisal of current diagnostic criteria. Hum Pathol 1988; 19: 13406.
  • 21
    Silverberg SG, Kurman RJ. Tumors of the uterine corpus and gestational trophoblastic disease. In: Atlas of tumor pathology, third series, fascicle 3. Washington, DC: Armed Forces Institute of Pathology, 1993: 47.